SV News
6 July 2023SV NewsDDF: Unleashing innovation, a new era for dementia- 28 June 2023SV NewsRenowned Neuroscientist Prof. Michael Heneka, M.D, Joins The Dementia Discovery Fund (DDF) as Scientific Advisor
31 May 2023Portfolio NewsCumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer's Dementia Validation Trial
31 May 2023Portfolio NewsViolet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham Ventures (MGBV)- 19 May 2023SV NewsFirst Steps to Treating Dementia May Lie in Related Diseases
15 May 2023Portfolio NewsTherini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease- 27 April 2023Portfolio NewsTherini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
18 April 2023Portfolio NewsNitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting- 6 April 2023Portfolio NewsQurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS
- 9 March 2023Portfolio NewsALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies
- 9 March 2023Portfolio NewsQurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
23 February 2023Portfolio NewsAviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology
